Treatment of benign prostatic hyperplasia in patients with cardiovascular disease

Vincent M. Santillo, Franklin C. Lowe

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and α-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the α-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older α-adrenoceptor antagonists, terazosin and doxazosin, were initially approved for the treatment of hypertension and are associated with higher rates of dizziness, syncope and hypotension than the newer agents, tamsulosin and alfuzosin. The older α-adrenoceptor antagonists are also involved in more interactions and have a greater number of precautions concerning their usage with other cardiovascular medications. Of the newer α-adrenoceptor antagonists, tamsulosin has a lower rate of dizziness than alfuzosin. However, both of these agents are superior to doxazosin and terazosin in that no dose escalation or titration is needed for them.

Original languageEnglish (US)
Pages (from-to)795-805
Number of pages11
JournalDrugs and Aging
Volume23
Issue number10
StatePublished - 2006
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Terazosin
Adrenergic Receptors
tamsulosin
Cardiovascular Diseases
Doxazosin
Dizziness
Therapeutics
Syncope
Cardiovascular System
Hypotension
Pharmacology
Hypertension
alfuzosin

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

Treatment of benign prostatic hyperplasia in patients with cardiovascular disease. / Santillo, Vincent M.; Lowe, Franklin C.

In: Drugs and Aging, Vol. 23, No. 10, 2006, p. 795-805.

Research output: Contribution to journalArticle

@article{4680bad6d6ee41eea75b335787a75440,
title = "Treatment of benign prostatic hyperplasia in patients with cardiovascular disease",
abstract = "Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and α-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the α-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older α-adrenoceptor antagonists, terazosin and doxazosin, were initially approved for the treatment of hypertension and are associated with higher rates of dizziness, syncope and hypotension than the newer agents, tamsulosin and alfuzosin. The older α-adrenoceptor antagonists are also involved in more interactions and have a greater number of precautions concerning their usage with other cardiovascular medications. Of the newer α-adrenoceptor antagonists, tamsulosin has a lower rate of dizziness than alfuzosin. However, both of these agents are superior to doxazosin and terazosin in that no dose escalation or titration is needed for them.",
author = "Santillo, {Vincent M.} and Lowe, {Franklin C.}",
year = "2006",
language = "English (US)",
volume = "23",
pages = "795--805",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Treatment of benign prostatic hyperplasia in patients with cardiovascular disease

AU - Santillo, Vincent M.

AU - Lowe, Franklin C.

PY - 2006

Y1 - 2006

N2 - Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and α-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the α-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older α-adrenoceptor antagonists, terazosin and doxazosin, were initially approved for the treatment of hypertension and are associated with higher rates of dizziness, syncope and hypotension than the newer agents, tamsulosin and alfuzosin. The older α-adrenoceptor antagonists are also involved in more interactions and have a greater number of precautions concerning their usage with other cardiovascular medications. Of the newer α-adrenoceptor antagonists, tamsulosin has a lower rate of dizziness than alfuzosin. However, both of these agents are superior to doxazosin and terazosin in that no dose escalation or titration is needed for them.

AB - Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and α-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the α-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older α-adrenoceptor antagonists, terazosin and doxazosin, were initially approved for the treatment of hypertension and are associated with higher rates of dizziness, syncope and hypotension than the newer agents, tamsulosin and alfuzosin. The older α-adrenoceptor antagonists are also involved in more interactions and have a greater number of precautions concerning their usage with other cardiovascular medications. Of the newer α-adrenoceptor antagonists, tamsulosin has a lower rate of dizziness than alfuzosin. However, both of these agents are superior to doxazosin and terazosin in that no dose escalation or titration is needed for them.

UR - http://www.scopus.com/inward/record.url?scp=33750495394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750495394&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 795

EP - 805

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 10

ER -